<DOC>
	<DOCNO>NCT02406911</DOCNO>
	<brief_summary>Antiplatelet treatment patient end stage renal disease ( ESRD ) hemodialysis ( HD ) still challenge bleed thrombotic complication . The investigator hypothesize ticagrelor daily dose would achieve tolerable antiplatelet effect compare ticagrelor twice day dose ESRD patient HD .</brief_summary>
	<brief_title>Ticagrelor Anti-inflammatory Effects</brief_title>
	<detailed_description>Chronic kidney disease ( CKD ) strong risk factor cardiovascular morbidity mortality , confers increase risk stent thrombosis even dual antiplatelet therapy ( clopidogrel aspirin ) administer . Patients severe CKD end stage renal disease ( ESRD ) hemodialysis ( HD ) exhibit high platelet reactivity clopidogrel normal renal function . The investigator recently report platelet inhibition ticagrelor faster markedly great clopidogrel onset dose regimen patient ESRD HD . However , study conduct whether platelet reactivity ticagrelor treatment associate endothelial function , platelet activation marker inflammation status ESRD patient HD . Additionally , dose dependent effect ticagrelor rarely evaluate .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>ESRD patient undergo regular ( ≥ 6 month ) maintenance HD ongoing ( ≥ 2 month ) treatment clopidogrel P2Y12 reaction unit ( PRUs ) 235 know allergy aspirin , clopidogrel , ticagrelor concomitant use antithrombotic drug ( oral anticoagulant , dipyridamole ) thrombocytopenia ( platelet count &lt; 100,000/mm3 ) hematocrit &lt; 25 % uncontrolled hyperglycemia ( hemoglobin A1c &gt; 10 % ) liver disease ( bilirubin level &gt; 2 mg/dl ) symptomatic severe pulmonary disease active bleeding bleed diathesis gastrointestinal bleeding within last 6 month hemodynamic instability acute coronary cerebrovascular event within last 3 month pregnancy malignancy concomitant use cytochrome P450 inhibitor nonsteroidal antiinflammatory drug recent treatment ( &lt; 30 day ) glycoprotein IIb/IIIa antagonist</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>platelet</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
</DOC>